319 related articles for article (PubMed ID: 28965585)
21. [Oral zinc in Wilson disease--an alternative to D-penicillamine].
Ramadori G; Keidl E; Hütteroth T; Dormeyer HH; Manns M; Meyer zum Büschenfelde KH
Z Gastroenterol; 1985 Jan; 23(1):25-9. PubMed ID: 4060799
[TBL] [Abstract][Full Text] [Related]
22. The effect of long term treatment with penicillamine on the copper content in the liver in patients with Wilson's disease.
Marecek Z; Heyrovský A; Volek V
Acta Hepatogastroenterol (Stuttg); 1975 Oct; 22(5):292-6. PubMed ID: 1199668
[TBL] [Abstract][Full Text] [Related]
23. Zinc therapy in Wilson's disease: observations in five patients.
Rossaro L; Sturniolo GC; Giacon G; Montino MC; Lecis PE; Schade RR; Corazza GR; Trevisan C; Naccarato R
Am J Gastroenterol; 1990 Jun; 85(6):665-8. PubMed ID: 2353684
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of oral chelators in treatment of patients with Wilson disease.
Weiss KH; Thurik F; Gotthardt DN; Schäfer M; Teufel U; Wiegand F; Merle U; Ferenci-Foerster D; Maieron A; Stauber R; Zoller H; Schmidt HH; Reuner U; Hefter H; Trocello JM; Houwen RH; Ferenci P; Stremmel W;
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1028-35.e1-2. PubMed ID: 23542331
[TBL] [Abstract][Full Text] [Related]
25. Determination of copper poisoning in Wilson's disease using laser ablation inductively coupled plasma mass spectrometry.
Weiskirchen S; Kim P; Weiskirchen R
Ann Transl Med; 2019 Apr; 7(Suppl 2):S72. PubMed ID: 31179309
[TBL] [Abstract][Full Text] [Related]
26. 1H NMR-based metabolomics investigation of copper-laden rat: a model of Wilson's disease.
Xu J; Jiang H; Li J; Cheng KK; Dong J; Chen Z
PLoS One; 2015; 10(4):e0119654. PubMed ID: 25849323
[TBL] [Abstract][Full Text] [Related]
27. Relationship between striatal glucose consumption and copper excretion in patients with Wilson's disease treated with D-penicillamine.
Hefter H; Kuwert T; Herzog H; Arendt G; Stremmel W; Feinendegen LE
J Neurol; 1993 Nov; 241(1):49-53. PubMed ID: 8138822
[TBL] [Abstract][Full Text] [Related]
28. [The onset of psychiatric disorders and Wilson's disease].
Benhamla T; Tirouche YD; Abaoub-Germain A; Theodore F
Encephale; 2007 Dec; 33(6):924-32. PubMed ID: 18789784
[TBL] [Abstract][Full Text] [Related]
29. Zinc monotherapy is effective in Wilson's disease patients with mild liver disease diagnosed in childhood: a retrospective study.
Ranucci G; Di Dato F; Spagnuolo MI; Vajro P; Iorio R
Orphanet J Rare Dis; 2014 Mar; 9():41. PubMed ID: 24661374
[TBL] [Abstract][Full Text] [Related]
30. Effect of penicillamine and zinc on iron metabolism in Wilson's disease.
Medici V; Di Leo V; Lamboglia F; Bowlus CL; Tseng SC; D'Incà R; Irato P; Burra P; Martines D; Sturniolo GC
Scand J Gastroenterol; 2007 Dec; 42(12):1495-500. PubMed ID: 17994470
[TBL] [Abstract][Full Text] [Related]
31. Clinical efficacy and safety of chelation treatment with typical penicillamine in cross combination with DMPS repeatedly for Wilson's disease.
Xu SQ; Li XF; Zhu HY; Liu Y; Fang F; Chen L
J Huazhong Univ Sci Technolog Med Sci; 2013 Oct; 33(5):743-747. PubMed ID: 24142730
[TBL] [Abstract][Full Text] [Related]
32. A clinical study of Wilson's disease: The experience of a single Egyptian Paediatric Hepatology Unit.
El-Karaksy H; Fahmy M; El-Raziky MS; El-Hawary M; El-Sayed R; El-Koofy N; El-Mougy F; El-Hennawy A; El-Shabrawi M
Arab J Gastroenterol; 2011 Sep; 12(3):125-30. PubMed ID: 22055589
[TBL] [Abstract][Full Text] [Related]
33. Copper and zinc in the serum, urine, and hair of patients with Wilson's disease treated with penicillamine and zinc.
Dastych M; Procházková D; Pokorný A; Zdrazil L
Biol Trace Elem Res; 2010 Mar; 133(3):265-9. PubMed ID: 19562272
[TBL] [Abstract][Full Text] [Related]
34. Treatment of Wilson's disease with zinc from the time of diagnosis in pediatric patients: a single-hospital, 10-year follow-up study.
Marcellini M; Di Ciommo V; Callea F; Devito R; Comparcola D; Sartorelli MR; Carelli G; Nobili V
J Lab Clin Med; 2005 Mar; 145(3):139-43. PubMed ID: 15871305
[TBL] [Abstract][Full Text] [Related]
35. A study of susceptibility-weighted imaging in patients with Wilson disease during the treatment of metal chelator.
Zhou X; Xiao X; Li XH; Qin HL; Pu XY; Chen DB; Wu C; Feng L; Liang XL
J Neurol; 2020 Jun; 267(6):1643-1650. PubMed ID: 32060651
[TBL] [Abstract][Full Text] [Related]
36. [Pathogenesis and treatment of Wilson's disease].
Nagy J; Vincze Z; Folhoffer A; Horváth A; Csák T; Zelkó R
Acta Pharm Hung; 2003; 73(4):237-41. PubMed ID: 15279036
[TBL] [Abstract][Full Text] [Related]
37. Myelopathy secondary to copper deficiency as a complication of treatment of Wilson's disease.
Lozano Herrero J; Muñoz Bertrán E; Ortega González I; Gómez Espín R; López Espín MI
Gastroenterol Hepatol; 2012 Dec; 35(10):704-7. PubMed ID: 22609346
[TBL] [Abstract][Full Text] [Related]
38. Elemental bioimaging and speciation analysis for the investigation of Wilson's disease using μXRF and XANES.
Hachmöller O; Buzanich AG; Aichler M; Radtke M; Dietrich D; Schwamborn K; Lutz L; Werner M; Sperling M; Walch A; Karst U
Metallomics; 2016 Jul; 8(7):648-53. PubMed ID: 26999628
[TBL] [Abstract][Full Text] [Related]
39. Zinc treatment prevents lipid peroxidation and increases glutathione availability in Wilson's disease.
Farinati F; Cardin R; D'inca R; Naccarato R; Sturniolo GC
J Lab Clin Med; 2003 Jun; 141(6):372-7. PubMed ID: 12819634
[TBL] [Abstract][Full Text] [Related]
40. Treatment and management of Wilson's disease.
Shimizu N; Yamaguchi Y; Aoki T
Pediatr Int; 1999 Aug; 41(4):419-22. PubMed ID: 10453198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
